Safety and Risk of Medication Overuse Headache in Lasmiditan and Second-Generation Gepants: A Rapid Review

Flavia Lo Castro,1 Simona Guerzoni,1 Lanfranco Pellesi2 1Medical Toxicology, Headache and Drug Abuse Research Center, Department of Specialized Medicine, AOU Policlinico di Modena, Modena, Italy; 2Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lo Castro F, Guerzoni S, Pellesi L
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	cgrp headache migraine moh triptans Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/052562f361c14f4fa8681714a9809356
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:052562f361c14f4fa8681714a9809356
record_format	dspace
spelling	oai:doaj.org-article:052562f361c14f4fa8681714a98093562021-11-23T18:43:01ZSafety and Risk of Medication Overuse Headache in Lasmiditan and Second-Generation Gepants: A Rapid Review1179-1365https://doaj.org/article/052562f361c14f4fa8681714a98093562021-11-01T00:00:00Zhttps://www.dovepress.com/safety-and-risk-of-medication-overuse-headache-in-lasmiditan-and-secon-peer-reviewed-fulltext-article-DHPShttps://doaj.org/toc/1179-1365Flavia Lo Castro,1 Simona Guerzoni,1 Lanfranco Pellesi2 1Medical Toxicology, Headache and Drug Abuse Research Center, Department of Specialized Medicine, AOU Policlinico di Modena, Modena, Italy; 2Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkCorrespondence: Lanfranco PellesiDanish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkTel +45 53 80 30 56Email lanfranco.pellesi@gmail.comAbstract: The treatment of migraine is often complicated by insufficient headache relief, a miscellany of side effects and the risk of developing Medication Overuse Headache (MOH). Novel acute therapies have been recently developed and are now in the early post-marketing phase. Lasmiditan is a highly selective serotonin receptor agonist that binds to the 5-HT1F receptor, while ubrogepant and rimegepant antagonize the calcitonin gene-related peptide receptor. All three medications are now prescribed in a real-world setting, and an adequate level of knowledge is the starting point for rational use. In this rapid systematic review, we have established what is known about lasmiditan, ubrogepant and rimegepant, highlighting the most relevant safety aspects available from published studies and speculating about their risk of MOH.Keywords: CGRP, headache, migraine, MOH, triptansLo Castro FGuerzoni SPellesi LDove Medical PressarticlecgrpheadachemigrainemohtriptansMedicine (General)R5-920ENDrug, Healthcare and Patient Safety, Vol Volume 13, Pp 233-240 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	cgrp headache migraine moh triptans Medicine (General) R5-920
spellingShingle	cgrp headache migraine moh triptans Medicine (General) R5-920 Lo Castro F Guerzoni S Pellesi L Safety and Risk of Medication Overuse Headache in Lasmiditan and Second-Generation Gepants: A Rapid Review
description	Flavia Lo Castro,1 Simona Guerzoni,1 Lanfranco Pellesi2 1Medical Toxicology, Headache and Drug Abuse Research Center, Department of Specialized Medicine, AOU Policlinico di Modena, Modena, Italy; 2Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkCorrespondence: Lanfranco PellesiDanish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkTel +45 53 80 30 56Email lanfranco.pellesi@gmail.comAbstract: The treatment of migraine is often complicated by insufficient headache relief, a miscellany of side effects and the risk of developing Medication Overuse Headache (MOH). Novel acute therapies have been recently developed and are now in the early post-marketing phase. Lasmiditan is a highly selective serotonin receptor agonist that binds to the 5-HT1F receptor, while ubrogepant and rimegepant antagonize the calcitonin gene-related peptide receptor. All three medications are now prescribed in a real-world setting, and an adequate level of knowledge is the starting point for rational use. In this rapid systematic review, we have established what is known about lasmiditan, ubrogepant and rimegepant, highlighting the most relevant safety aspects available from published studies and speculating about their risk of MOH.Keywords: CGRP, headache, migraine, MOH, triptans
format	article
author	Lo Castro F Guerzoni S Pellesi L
author_facet	Lo Castro F Guerzoni S Pellesi L
author_sort	Lo Castro F
title	Safety and Risk of Medication Overuse Headache in Lasmiditan and Second-Generation Gepants: A Rapid Review
title_short	Safety and Risk of Medication Overuse Headache in Lasmiditan and Second-Generation Gepants: A Rapid Review
title_full	Safety and Risk of Medication Overuse Headache in Lasmiditan and Second-Generation Gepants: A Rapid Review
title_fullStr	Safety and Risk of Medication Overuse Headache in Lasmiditan and Second-Generation Gepants: A Rapid Review
title_full_unstemmed	Safety and Risk of Medication Overuse Headache in Lasmiditan and Second-Generation Gepants: A Rapid Review
title_sort	safety and risk of medication overuse headache in lasmiditan and second-generation gepants: a rapid review
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/052562f361c14f4fa8681714a9809356
work_keys_str_mv	AT locastrof safetyandriskofmedicationoveruseheadacheinlasmiditanandsecondgenerationgepantsarapidreview AT guerzonis safetyandriskofmedicationoveruseheadacheinlasmiditanandsecondgenerationgepantsarapidreview AT pellesil safetyandriskofmedicationoveruseheadacheinlasmiditanandsecondgenerationgepantsarapidreview
_version_	1718416133131862016

Safety and Risk of Medication Overuse Headache in Lasmiditan and Second-Generation Gepants: A Rapid Review

Ejemplares similares